Burcon NutraScience
Burcon NutraScience Corporation, together with its subsidiary, develops plant protein extraction and purification technology of functional and renewable plant proteins in Canada. The last earnings update was 34 days ago. More info.
Add to Portfolio Compare Print
- Burcon NutraScience has significant price volatility in the past 3 months.
BU Share Price and Events
7 Day Returns
1 Year Returns
BU Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Burcon NutraScience (BU) | -14.5% | 41.3% | 132.1% | -44% | -90.7% | -93% |
| CA Chemicals | -0.2% | 0.7% | 16.4% | 9.8% | 48.4% | -5.6% |
| CA Market | 0.3% | 2% | 13.2% | 0.7% | 16.6% | 5.6% |
1 Year Return vs Industry and Market
- BU underperformed the Chemicals industry which returned 9.8% over the past year.
- BU underperformed the Market in Canada which returned 0.7% over the past year.
BU Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether Burcon NutraScience is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Burcon NutraScience has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for Burcon NutraScience. This is due to cash flow or dividend data being unavailable. The share price is CA$0.325.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Burcon NutraScience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Burcon NutraScience's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in CAD | CA$-0.11 |
| TSX:BU Share Price ** | TSX (2019-03-20) in CAD | CA$0.33 |
| Canada Chemicals Industry PE Ratio | Median Figure of 6 Publicly-Listed Chemicals Companies | 9.3x |
| Canada Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 14.78x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Burcon NutraScience.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = TSX:BU Share Price ÷ EPS (both in CAD) = 0.33 ÷ -0.11 |
-2.85x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Burcon NutraScience is loss making, we can't compare its value to the CA Chemicals industry average.
- Burcon NutraScience is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does
Burcon NutraScience's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.85x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| North America Chemicals Industry PEG Ratio | Median Figure of 49 Publicly-Listed Chemicals Companies | 1.47x |
| Canada Market PEG Ratio | Median Figure of 253 Publicly-Listed Companies | 1.2x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Burcon NutraScience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Burcon NutraScience's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in CAD | CA$-0.02 |
| TSX:BU Share Price * | TSX (2019-03-20) in CAD | CA$0.33 |
| Canada Chemicals Industry PB Ratio | Median Figure of 29 Publicly-Listed Chemicals Companies | 1.34x |
| Canada Market PB Ratio | Median Figure of 2,349 Publicly-Listed Companies | 1.58x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = TSX:BU Share Price ÷ Book Value per Share (both in CAD) = 0.33 ÷ -0.02 |
-17.96x |
* Primary Listing of Burcon NutraScience.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Burcon NutraScience has negative assets, we can't compare the value of its assets to the CA Chemicals industry average.
Value checks
We assess Burcon NutraScience's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check) Burcon NutraScience has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
BU Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Burcon NutraScience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Burcon NutraScience's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Burcon NutraScience's earnings growth to the Canada market average as no estimate data is available.
- Unable to compare Burcon NutraScience's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Canada Chemicals Industry Earnings Growth Rate | Market Cap Weighted Average | 28.4% |
| Canada Chemicals Industry Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 17.8% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 6.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 0 | -4 | -5 |
| 2018-09-30 | 0 | -5 | -5 |
| 2018-06-30 | 0 | -5 | -5 |
| 2018-03-31 | 0 | -5 | -6 |
| 2017-12-31 | 0 | -4 | -6 |
| 2017-09-30 | 0 | -4 | -5 |
| 2017-06-30 | 0 | -5 | -6 |
| 2017-03-31 | 0 | -5 | -6 |
| 2016-12-31 | 0 | -5 | -6 |
| 2016-09-30 | 0 | -5 | -6 |
| 2016-06-30 | 0 | -5 | -6 |
| 2016-03-31 | 0 | -5 | -7 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Burcon NutraScience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|
| Date (Data in CAD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.11 |
| 2018-09-30 | -0.13 |
| 2018-06-30 | -0.13 |
| 2018-03-31 | -0.15 |
| 2017-12-31 | -0.15 |
| 2017-09-30 | -0.15 |
| 2017-06-30 | -0.15 |
| 2017-03-31 | -0.16 |
| 2016-12-31 | -0.17 |
| 2016-09-30 | -0.18 |
| 2016-06-30 | -0.18 |
| 2016-03-31 | -0.18 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Burcon NutraScience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Burcon NutraScience's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Burcon NutraScience has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
BU Past Performance
How has Burcon NutraScience performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Burcon NutraScience does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Burcon NutraScience's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Burcon NutraScience's 1-year growth to the North America Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Burcon NutraScience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 0.04 | -4.93 | 1.97 | 1.62 |
| 2018-09-30 | 0.04 | -5.29 | 2.05 | 1.68 |
| 2018-06-30 | 0.03 | -5.27 | 1.93 | 1.77 |
| 2018-03-31 | 0.05 | -5.62 | 2.05 | 1.85 |
| 2017-12-31 | 0.05 | -5.59 | 1.90 | 1.97 |
| 2017-09-30 | 0.07 | -5.46 | 2.23 | 1.98 |
| 2017-06-30 | 0.08 | -5.62 | 2.38 | 2.05 |
| 2017-03-31 | 0.09 | -5.78 | 2.40 | 2.15 |
| 2016-12-31 | 0.11 | -6.02 | 2.53 | 2.24 |
| 2016-09-30 | 0.11 | -6.30 | 2.48 | 2.43 |
| 2016-06-30 | 0.11 | -6.40 | 2.64 | 2.48 |
| 2016-03-31 | 0.11 | -6.57 | 2.73 | 2.56 |
| 2015-12-31 | 0.10 | -6.50 | 3.27 | 2.58 |
| 2015-09-30 | 0.11 | -6.66 | 3.76 | 2.55 |
| 2015-06-30 | 0.11 | -6.94 | 4.31 | 2.57 |
| 2015-03-31 | 0.11 | -6.58 | 2.71 | 2.45 |
| 2014-12-31 | 0.10 | -6.28 | 4.19 | 2.38 |
| 2014-09-30 | 0.10 | -5.99 | 4.06 | 2.33 |
| 2014-06-30 | 0.10 | -5.77 | 3.87 | 2.30 |
| 2014-03-31 | 0.09 | -5.96 | 4.04 | 2.31 |
| 2013-12-31 | 0.09 | -6.13 | 4.08 | 2.33 |
| 2013-09-30 | 0.08 | -6.34 | 4.19 | 2.31 |
| 2013-06-30 | 0.05 | -6.09 | 3.91 | 2.31 |
| 2013-03-31 | 0.03 | -5.55 | 3.64 | 2.02 |
| 2012-12-31 | 0.01 | -5.23 | 3.61 | 1.72 |
| 2012-09-30 | -5.37 | 3.88 | 1.60 | |
| 2012-06-30 | -5.81 | 4.69 | 1.24 | |
| 2012-03-31 | -5.96 | 5.10 | 1.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Burcon NutraScience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Burcon NutraScience has efficiently used its assets last year compared to the CA Chemicals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Burcon NutraScience improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess Burcon NutraScience's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Burcon NutraScience has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
BU Health
How is Burcon NutraScience's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Burcon NutraScience's finances.
The net worth of a company is the difference between its assets and liabilities.
- Burcon NutraScience's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Burcon NutraScience has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Burcon NutraScience has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Burcon NutraScience Company Filings, last reported 2 months ago.
| Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -0.80 | 2.47 | 0.75 |
| 2018-09-30 | 0.30 | 1.95 | 1.12 |
| 2018-06-30 | 1.34 | 1.93 | 2.13 |
| 2018-03-31 | 2.35 | 1.91 | 3.42 |
| 2017-12-31 | 0.25 | 1.88 | 1.29 |
| 2017-09-30 | 1.66 | 1.86 | 2.33 |
| 2017-06-30 | 2.81 | 1.84 | 3.46 |
| 2017-03-31 | 4.11 | 1.82 | 4.70 |
| 2016-12-31 | 5.38 | 1.80 | 5.85 |
| 2016-09-30 | 1.38 | 1.77 | 1.71 |
| 2016-06-30 | 2.68 | 1.75 | 2.95 |
| 2016-03-31 | 4.11 | 0.00 | 2.48 |
| 2015-12-31 | 5.19 | 0.00 | 3.29 |
| 2015-09-30 | 6.47 | 0.00 | 4.43 |
| 2015-06-30 | 7.56 | 0.00 | 5.64 |
| 2015-03-31 | 5.79 | 0.00 | 3.67 |
| 2014-12-31 | 5.24 | 0.00 | 2.95 |
| 2014-09-30 | 6.69 | 0.00 | 4.18 |
| 2014-06-30 | 8.04 | 0.00 | 5.41 |
| 2014-03-31 | 4.32 | 0.00 | 1.39 |
| 2013-12-31 | 5.47 | 0.00 | 2.55 |
| 2013-09-30 | 6.73 | 0.00 | 3.96 |
| 2013-06-30 | 8.25 | 0.00 | 5.41 |
| 2013-03-31 | 9.75 | 0.00 | 6.69 |
| 2012-12-31 | 11.06 | 0.00 | 7.84 |
| 2012-09-30 | 7.28 | 0.00 | 3.98 |
| 2012-06-30 | 8.45 | 0.00 | 5.06 |
| 2012-03-31 | 9.39 | 0.00 | 6.16 |
- Burcon NutraScience has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Burcon NutraScience's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Burcon NutraScience has less than a year of cash runway based on current free cash flow.
- Burcon NutraScience has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.6% each year.
Financial health checks
We assess Burcon NutraScience's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Burcon NutraScience has a total score of 1/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
BU Dividends
What is Burcon NutraScience's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Burcon NutraScience
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Burcon NutraScience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Burcon NutraScience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| North America Chemicals Industry Average Dividend Yield | Market Cap Weighted Average of 55 Stocks | 2.3% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 330 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in CA$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Burcon NutraScience has not reported any payouts.
- Unable to verify if Burcon NutraScience's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Burcon NutraScience's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Burcon NutraScience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Burcon NutraScience has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
BU Management
CEO
| COMPENSATION | CA$294,024 |
| AGE | 55 |
| TENURE AS CEO | 0.2 years |
CEO Bio
Mr. Johann Franz Tergesen, MBA, CPA, CA, serves as the President and Chief Operating Officer of Burcon NutraScience Corporation (formerly Burcon Capital Corp.) and serves as the Chief Executive Officer since January 15, 2019. Mr. Tergesen serves as the Chief Executive Officer at Buyatab Online Inc. He served as Vice President and Treasurer of Burcon Properties Limited. He has been with the Burcon group of companies since December of 1995. He served as a Manager in the corporate finance group of the Vancouver office of Coopers & Lybrand, Chartered Accountants. He serves as Director at Buyatab Online Inc. He served as a Director at Burcon NutraScience Corporation since November 3, 1998 to September 12, 2012. He served as a Director of West Fourth Capital Corporation since May 17, 2007. He has been a Member of Advisory Board at Functional Technologies Corp. since March 2008. Mr. Tergesen holds a B.A. in economics from the University of Winnipeg and an M.B.A. from McGill University and is a Member of the Canadian Institute of Chartered Accountants.
CEO Compensation
- Johann's compensation has been consistent with company performance over the past year.
- Johann's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the Burcon NutraScience management team in years:
- The average tenure for the Burcon NutraScience management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Johann Tergesen
President
CA$294K
55
0.2 yrs
Jade Cheng
CFO & Treasurer
CA$193K
Dorothy Law
Senior VP of Legal & Corporate Secretary
CA$145K
49
9.5 yrs
Randy Willardsen
Senior Vice President of Process
CA$142K
17.3 yrs
Martin Schweizer
Vice President of Technical Development
CA$183K
9.5 yrs
Board of Directors Tenure
Average tenure and age of the Burcon NutraScience board of directors in years:
- The tenure for the Burcon NutraScience board of directors is about average.
Board of Directors
David Lorne Tyrrell
Chairman & Lead Director
CA$31K
75
0.2 yrs
Doug Gilpin
Director
CA$33K
79
7.5 yrs
Rosanna Chau
Director
CA$23K
63
20.3 yrs
Alan Chan
Director
CA$22K
8.9 yrs
Peter Kappel
Director
CA$32K
3.2 yrs
David Ju
Independent Director
CA$21K
1.3 yrs
Paul Westdal
Director Emeritus
CA$5K
Who owns this company?
Recent Insider Trading
- Burcon NutraScience insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 17. Jan 19 | Buy | PT International Development Corporation Limited | Company | 14. Jan 19 | 14. Jan 19 | 1,566,719 | CA$0.20 | CA$311,778 | ||
| 16. Jan 19 | Sell | Allan Yap | Individual | 14. Jan 19 | 14. Jan 19 | -1,566,719 | CA$0.20 | CA$-313,344 | ||
| 08. Jan 19 | Buy | Johann Tergesen | Individual | 04. Jan 19 | 04. Jan 19 | 20,000 | CA$0.16 | CA$3,200 | ||
| 20. Dec 18 | Buy | Johann Tergesen | Individual | 19. Dec 18 | 19. Dec 18 | 50,000 | CA$0.15 | CA$7,050 | ||
| 18. Dec 18 | Buy | Johann Tergesen | Individual | 17. Dec 18 | 18. Dec 18 | 120,000 | CA$0.17 | CA$19,001 | ||
| 17. Dec 18 | Buy | Johann Tergesen | Individual | 11. Dec 18 | 14. Dec 18 | 70,000 | CA$0.23 | CA$15,441 | ||
Management checks
We assess Burcon NutraScience's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Burcon NutraScience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
BU News
Simply Wall St News
What does Burcon Nutrascience Corporation's (TSE:BU) Balance Sheet Tell Us About Its Future?
Burcon Nutrascience Corporation (TSE:BU) is a small-cap stock with a market capitalization of CA$23.73m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health.
Simply Wall St - – Full articleWho Owns Burcon Nutrascience Corporation (TSE:BU)?
In this article, I'm going to take a look at Burcon Nutrascience Corporation’s (TSX:BU) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Private Company Ownership Potential investors in BU should also look at another important group of investors: private companies, with a stake of 4.15%, who are primarily invested because of strategic and capital gain interests.
Simply Wall St - – Full articleShould You Worry About Burcon Nutrascience Corporation's (TSE:BU) CEO Salary Level?
Profitability of a company is a strong indication of BU's ability to generate returns on shareholders' funds through corporate activities. … Normally I would use earnings and market cap to account for variations in performance, however, BU's negative earnings reduces the usefulness of my formula. … Its important for shareholders to be active in voting governance decisions, as board members are only representatives of investors' voices.
Simply Wall St - – Full articleHow Should You Think About Burcon Nutrascience Corporation's (TSE:BU) Risks?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … See our latest analysis for Burcon Nutrascience What does BU's beta value mean? … Thus, we can expect BU to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleIs Burcon Nutrascience Corporation (TSE:BU) Growing Too Fast?
Looking at Burcon Nutrascience’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … Given the level of cash left in the bank, if Burcon Nutrascience maintained its opex level of CA$3.86M, it will still run out of cash within the next couples of months. … The cash burn analysis result indicates a cash constraint for the company, due to its current level of cash reserves.
Simply Wall St - – Full articleAre Earnings Prospects Improving For Loss-Making Burcon Nutrascience Corporation's (TSE:BU)?
Check out our latest analysis for Burcon Nutrascience Could BU beat the long-term trend and outperform its industry? … TSX:BU Income Statement Mar 22nd 18 We can further analyze Burcon Nutrascience's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Burcon Nutrascience's top-line has increased by a mere 7.75%, on average.
Simply Wall St - – Full articleWhat Investors Should Know About Burcon Nutrascience Corporation's (TSE:BU) Financial Strength
How does BU’s operating cash flow stack up against its debt? … Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.Next Steps: BU’s debt and cash flow levels indicate room for improvement.
Simply Wall St - – Full articleIs Burcon Nutrascience Corporation (TSE:BU) Overpaying Its CEO?
Usually I would use earnings and market cap to account for variations in performance, however, BU's negative earnings reduces the effectiveness of this method. … Although remuneration can be a useful gauge of whether Yap's incentives are well-aligned with BU's shareholders, it is certainly not sufficient to base your investment decision solely on this factor. … To research more about these fundamentals, I recommend you check out our simple infographic report on BU's financial metrics.
Simply Wall St - – Full articleIs This A Catalyst To Buy Burcon Nutrascience Corporation (TSE:BU)?
Burcon Nutrascience faces the trade-off between running the risk of depleting its cash reserves too fast, or risk falling behind its profitable competitors by investing too slowly. … TSX:BU Income Statement Dec 18th 17 When will Burcon Nutrascience need to raise more cash? … However, even with declining costs, the current level of cash is not enough to sustain Burcon Nutrascience’s operations and the company may need to come to market to raise more capital within the year.
Simply Wall St - – Full articleWant To Invest In Burcon Nutrascience Corporation (TSX:BU)? Here's How It Performed Lately
Investors with a long-term horizong may find it valuable to assess Burcon Nutrascience Corporation's (TSX:BU) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. … I look at data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Burcon Nutrascience's latest twelve-month earnings -CA$5.5M, which, in comparison to the prior year's figure, has become less negative.
Simply Wall St - – Full articleBU Company Info
Description
Burcon NutraScience Corporation, together with its subsidiary, develops plant protein extraction and purification technology of functional and renewable plant proteins in Canada. Its products include CLARISOY, a soy protein for dairy foods, neutral pH beverages, and coffee creamers/whiteners; and Peazazz, a novel pea protein isolate. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. Burcon NutraScience Corporation was founded in 1998 and is headquartered in Vancouver, Canada.
Details
| Name: | Burcon NutraScience Corporation |
| BU | |
| Exchange: | TSX |
| Founded: | 1998 |
| CA$14,280,998 | |
| 43,941,535 | |
| Website: | http://www.burcon.ca |
| Address: |
Burcon NutraScience Corporation 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2, Canada |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| TSX | BU | Common Shares | The Toronto Stock Exchange | CA | CAD | 19. Feb 1999 | |
| OTCPK | BURO.F | Common Shares | Pink Sheets LLC | US | USD | 19. Feb 1999 | |
| DB | BNE | Common Shares | Deutsche Boerse AG | DE | EUR | 19. Feb 1999 |
Number of employees
Current staff
Industry
| Specialty Chemicals | |
| Materials |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/03/20 23:33 |
| End of day share price update: | 2019/03/20 00:00 |
| Last estimates confirmation: | 2016/06/27 |
| Last earnings filing: | 2019/02/14 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
